Atul Deodhar - Concepedia

Author

Atul Deodhar

Also Known As

A A Deodhar, A Deodhar, A. A. DEODHAR, A. A. Deodhar, A. Deodhar, ATUL A. DEODHAR, ATUL DEODHAR, Atul A Deodhar, Atul A. Deodhar, Atul Deodhar

462

Publications

16.4K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University Rheumazentrum Ruhrgebiet Charité - Universitätsmedizin Berlin Leiden University Medical Center Novartis (Switzerland)

About

Atul Deodhar is an author at Oregon Health & Science University specializing in medicine, rheumatology, and orthopaedics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	35	3.1K
2	Health Sciences	3	3	56
3	Allergy	2	2	37
4	Applied Physiology	1	1	18
5	Diabetes	1	1	14

Atul Deodhar

133

Publications

11.6K

Citations

H-Index

Page 1

	Year	Citations
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis Dominique Baeten, Joachim Sieper, Jürgen Braun, New England Journal of Medicine	2015	973
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Michael M. Ward, Atul Deodhar, Lianne S. Gensler, Arthritis & Rheumatology RheumatologyTreatment Network RecommendationsNon-operative TreatmentSpondyloarthritisRheumatic Diseases	2019	597
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Michael M. Ward, Atul Deodhar, Elie A. Akl, Arthritis & Rheumatology	2015	544
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Arthritis & Rheumatology	2018	465
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study Robert Landewé, Jürgen Braun, Atul Deodhar, Annals of the Rheumatic Diseases	2013	462
Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial Clifton O. Bingham, R. John Looney, Atul Deodhar, Arthritis & Rheumatism	2009	458
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Philip J. Mease, Roy Fleischmann, Atul Deodhar, Annals of the Rheumatic Diseases	2013	453
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis Philip J. Mease, Mark C. Genovese, Maria Greenwald, New England Journal of Medicine	2014	384
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) P. Emery, Atul Deodhar, William F. C. Rigby, Annals of the Rheumatic Diseases	2010	345

Page 1